Cargando…

Safety of prolonged treatment with bedaquiline in programmatic conditions

Bedaquiline is now considered a first-line medicine for treatment of rifampicin-resistant tuberculosis (RR-TB). We evaluated the safety of treatment with bedaquiline for longer than 190 days in individuals with RR-TB under programmatic conditions. In a prospective cohort study enrolling pulmonary RR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhurkin, Dzmitriy, Gurbanova, Elmira, Campbell, Jonathon R., Menzies, Dick, Setkina, Svetlana, Hurevich, Hennadz, Solodovnikova, Varvara, Viatushka, Dzmitry, Altraja, Alan, Skrahina, Alena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108964/ https://www.ncbi.nlm.nih.gov/pubmed/35586446 http://dx.doi.org/10.1183/23120541.00685-2021

Ejemplares similares

Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study
por: Sereda, Yuliia, et al.
Publicado: (2022)

Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis
por: Skrahin, Aliaksandr, et al.
Publicado: (2016)

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience
por: Sinkou, Heorhi, et al.
Publicado: (2017)

QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study
por: Isralls, Sharon, et al.
Publicado: (2021)

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
por: Fox, Gregory J., et al.
Publicado: (2013)

Rapid tests reduce the burden of tuberculosis in Azerbaijan prisons: special emphasis on rifampicin-resistance
por: Gurbanova, E, et al.
Publicado: (2018)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Prolonged use of bedaquiline in the treatment for MDR-TB in a child
por: Gubkina, Marina F., et al.
Publicado: (2021)

Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory
por: Podlekareva, Daria N., et al.
Publicado: (2021)

Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline
por: Sarathy, Jickky Palmae, et al.
Publicado: (2019)

Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase
por: Kundu, Subhashri, et al.
Publicado: (2016)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus
por: Lindman, Marissa, et al.
Publicado: (2019)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Maleate salts of bedaquiline
por: Zeller, Matthias, et al.
Publicado: (2021)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
por: Ding, Yangming, et al.
Publicado: (2023)

Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Crystal structures of salts of bedaquiline
por: Okezue, Mercy, et al.
Publicado: (2020)

Improved Synthesis and Isolation of Bedaquiline
por: Lubanyana, Hlengekile, et al.
Publicado: (2020)

Salts and Polymorph Screens for Bedaquiline
por: Okezue, Mercy, et al.
Publicado: (2021)

Effects of programmatic interventions to improve the management of latent tuberculosis: a follow up study up to five months after implementation
por: Yanes-Lane, Mercedes, et al.
Publicado: (2021)

Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis
por: Campbell, Jonathon R, et al.
Publicado: (2020)

Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk
por: Skrahina, Alena, et al.
Publicado: (2012)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Deconstructing programmatic assessment
por: Wilkinson, Tim J, et al.
Publicado: (2018)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Correction to “Improved Synthesis and Isolation of Bedaquiline”
por: Lubanyana, Hlengekile, et al.
Publicado: (2020)

Public investments in the clinical development of bedaquiline
por: Gotham, Dzintars, et al.
Publicado: (2020)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Moe, S., et al.
Publicado: (2023)

Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?
por: Oxlade, Olivia, et al.
Publicado: (2021)

On the issue of costs in programmatic assessment
por: van der Vleuten, Cees P. M., et al.
Publicado: (2016)

COVID‐19 and programmatic assessment
por: Bala, Laksha, et al.
Publicado: (2020)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

“Weighting” the Evidence: How Much Bedaquiline Is Enough?
por: Brust, James C. M.
Publicado: (2023)

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021)

TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020)

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
por: van Beek, Stijn W, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_konkrucr1tu6uvq7sou761ec7a